v3.26.1
Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 30, 2026
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Jul. 09, 2026
Summary Of Significant Accounting Policies [Line Items]              
Common stock, shares outstanding   5,229,392   5,229,392   3,220,707  
Common stock, shares authorized   300,000,000   300,000,000   300,000,000  
Common stock, par value   $ 0.001   $ 0.001   $ 0.001  
Research and development   $ 49,007 $ 7,910 $ 55,904 $ 16,457    
Common stock shares issued   5,229,392   5,229,392   3,220,707  
Weighted average contractual life       15 years      
Type of Cost, Good or Service [Extensible List]       us-gaap:LicenseMember      
Pre Funded Warrants       3,742,562 796,827    
Private Placement | Subsequent Event              
Summary Of Significant Accounting Policies [Line Items]              
Proceeds from sale of common stock             $ 49,800
Common Stock | Private Placement | Subsequent Event              
Summary Of Significant Accounting Policies [Line Items]              
Offering price             $ 33.21
Common stock shares issued             1,418,071
May 2026 Warrants              
Summary Of Significant Accounting Policies [Line Items]              
Weighted average contractual life       4 years 10 months 6 days      
Exercise price of common stock warrants   $ 11   $ 11      
July 2026 Pre- Funded Warrants | Subsequent Event              
Summary Of Significant Accounting Policies [Line Items]              
Offering price             $ 33.209
Common stock shares issued             87,500
Exercise price of common stock warrants             $ 0.001
Trademarks              
Summary Of Significant Accounting Policies [Line Items]              
Amortization of intangible assets   $ 3 6 $ 3 $ 6    
In Process Research and Development              
Summary Of Significant Accounting Policies [Line Items]              
Research and development           $ 3,900  
Certificate of Deposit              
Summary Of Significant Accounting Policies [Line Items]              
Restricted cash used to collateralize a credit card   200   200   $ 200  
ATM Sales Agreement | Trademarks              
Summary Of Significant Accounting Policies [Line Items]              
Amortization of intangible assets   3,000 6,000 3,000 6,000    
Sales Agreement November 2019 | Transaction Expense              
Summary Of Significant Accounting Policies [Line Items]              
Proceeds from sale of common stock   43,200 $ 800 $ 43,200 $ 800    
Sale of common stock, number of shares     36,566 450,866 36,566    
Securities Purchase Agreement              
Summary Of Significant Accounting Policies [Line Items]              
Offering expenses $ 27,600            
Exercise price of common stock warrants $ 11            
Securities Purchase Agreement | 2026 Pre-Funded Warrants              
Summary Of Significant Accounting Policies [Line Items]              
Purchase of shares 2,727,272            
Offering price $ 11            
Exercise price $ 0.001            
Securities Purchase Agreement | May 2026 Warrants              
Summary Of Significant Accounting Policies [Line Items]              
Purchase of shares 1,363,636            
Jefferies LLC [Member] | Maximum              
Summary Of Significant Accounting Policies [Line Items]              
Proceeds from Issuance Initial Public Offering       $ 80,000      
Jefferies LLC [Member] | Transaction Expense              
Summary Of Significant Accounting Policies [Line Items]              
Proceeds from sale of common stock   80,000   $ 80,000      
Jefferies LLC [Member] | Sales Agreement November 2019 | Transaction Expense              
Summary Of Significant Accounting Policies [Line Items]              
Shares of common stock       34,652      
Proceeds from sale of common stock   $ 300   $ 300      
Ascendant Health Sciences Ltd [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Percenatage of equity issued and outstanding   7.50%   7.50%